![IconGems-Print](images/IconGems-Print.png)
505 – Clinical Trial Design IV
On the Similarity of Two Dose-Response Curves
Bo Jin
Pfizer Inc.
Kerry B. Barker
Pfizer Inc.
The 2014 FDA draft guidance of clinical pharmacology data to support a demonstration of biosimilarity to a reference product considers clinical pharmacology studies as a critical part in the clinical evaluations on similarity between biosimilars and reference products. A particular issue which remains to be unsettled is on the methodology to demonstrate similarity of two dose response curves. Assuming that dose response curve follows an E-max model, we focus on the discussions on the sensitive dose to detect differences and provide a statistical procedure to test the similarity of two dose response curves.